Prime Therapeutics named a finalist in the 2013 Awards for Best Practices in Health Care Consumer Engagement and Protection
ST. PAUL, Minn., Aug. 9, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), was selected as a finalist for URAC's 2013 Best Practices in Health Care Consumer Engagement and Protection Awards. Prime was selected for its Controlled Substance Drug Utilization Review (DUR) program, which is part of the GuidedHealth® platform.
The Controlled Substance DUR program helps health plans and physicians identify potential misuse and abuse of controlled substance medications. Doing so helps improve patient health and reduce health care costs. This is Prime's most widely used DUR program. It has been implemented by most of Prime's clients, including Florida Blue whose positive results were featured in the submission.
"Prime is honored to be named as a finalist for Best Practices in Health Care Consumer Engagement and Protection from URAC," said Eric Elliott, president and CEO at Prime Therapeutics. "This recognition validates the innovative work we've done to develop and implement an industry best practice for improving safety and lowering overall cost of care for our members."
Prime experts will be presenting the Controlled Substance DUR Program at URAC's 14th Annual Quality Summit held in Washington, D.C. in October.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves more than 21 million people. It is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.
For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.
SOURCE Prime Therapeutics